Seema Nayak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seema Nayak has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Madhu Mati Goel
Medanta Holding Pvt. Ltd., Lucknow, Uttar Pradesh, India
3 shared publicationsAbbas Ali Mahdi
Department of Biochemistry, King George’s Medical University, Lucknow, Uttar Pradesh, India
2 shared publicationsAnupam Mishra
Department of Otorhinolaryngology, King George’s Medical University, Lucknow, Uttar Pradesh, India
2 shared publicationsDivya Mehrotra
Department of Oral and Maxillofacial Surgery, King George’s Medical University, Lucknow, Uttar Pradesh, India
2 shared publicationsSeema Gupta
Department of Radiotherapy, King George’s Medical University, Lucknow, Uttar Pradesh, India
2 shared publications- Divya Mehrotra
Department of Oral and Maxillofacial Surgery, King George Medical University, Lucknow, India
1 shared publication
Latest Publications
- Open Access
- 11 June 2021
- Published by Scientific Scholar
- Vol. 08, 29-41
Aberrant Expression of PTPN-14 and Wilms’ Tumor 1 as Putative Biomarker for Locoregional Recurrence in Oral Squamous Cell Carcinoma
Objective Locoregional recurrence in oral squamous cell carcinoma (OSCC) is a major concern that leads to metastasis. Its detection at earliest stage is very important to increase the overall survival of the patient. There is no any biomarker for locoregional recurrence in oral squamous cell carcinoma (OSCC). The aim of this study was to find a biomarker for locoregional recurrence in tissue and serum at gene and protein level. Methods This work studied the expression of protein tyrosine phosphatase nonreceptor type 14 (PTPN-14) and Wilms’ tumor 1 (WT-1) in patients and correlated their expression with locoregional recurrence and survival. Tissue expression was observed in formalin fixed tissue biopsies of 96 OSCC and 32 healthy controls by immunohistochemistry using antibody against PTPN-14 and WT-1 and serum level was estimated by enzyme-linked immunosorbent assay in pre- and post-chemoradiotherapy samples. mRNA expression was determined by using real-time polymerase chain reaction. Patients were followed for 3 years for locoregional recurrence. Results Expression of PTPN-14 and WT-1 in OSCC was upregulated (aberrant) in tissue and sera in both gene and protein level as compared with healthy controls. Locoregional recurrence was observed in 10 (23.80%) patients and significantly associated with PTPN-14 (p < 0.047) and WT-1 expression (p < 0.031). Conclusion PTPN-14 and WT-1 may be used as biomarker to identify patients for higher risk of locoregional recurrence. This study drove molecular aspect and phenotypic level to derive new emergent strategies in future for recurrent OSCC.
- 11 June 2021
- Published by Scientific Scholar
- Vol. 08, 29-41
Open AccessAberrant Expression of PTPN-14 and Wilms’ Tumor 1 as Putative Biomarker for Locoregional Recurrence in Oral Squamous Cell Carcinoma
Objective Locoregional recurrence in oral squamous cell carcinoma (OSCC) is a major concern that leads to metastasis. Its detection at earliest stage is very important to increase the overall survival of the patient. There is no any biomarker for locoregional recurrence in oral squamous cell carcinoma (OSCC). The aim of this study was to find a biomarker for locoregional recurrence in tissue and serum at gene and protein level. Methods This work studied the expression of protein tyrosine phosphatase nonreceptor type 14 (PTPN-14) and Wilms’ tumor 1 (WT-1) in patients and correlated their expression with locoregional recurrence and survival. Tissue expression was observed in formalin fixed tissue biopsies of 96 OSCC and 32 healthy controls by immunohistochemistry using antibody against PTPN-14 and WT-1 and serum level was estimated by enzyme-linked immunosorbent assay in pre- and post-chemoradiotherapy samples. mRNA expression was determined by using real-time polymerase chain reaction. Patients were followed for 3 years for locoregional recurrence. Results Expression of PTPN-14 and WT-1 in OSCC was upregulated (aberrant) in tissue and sera in both gene and protein level as compared with healthy controls. Locoregional recurrence was observed in 10 (23.80%) patients and significantly associated with PTPN-14 (p < 0.047) and WT-1 expression (p < 0.031). Conclusion PTPN-14 and WT-1 may be used as biomarker to identify patients for higher risk of locoregional recurrence. This study drove molecular aspect and phenotypic level to derive new emergent strategies in future for recurrent OSCC.
- Open Access
- 28 January 2021
- Published by Taylor & Francis
- p. 93-100
IoT in agriculture
The internet of things (IoT) has plentiful applications in different fields. The initiative of IoT has shown a novel track of advanced research in agricultural dominion which is capable of offering many solutions toward the modernization of agriculture. Data are captured by mobile devices and sensors; for broadcasting data radio frequency (RF) technologies are used. To be persistent and functional in an effective way, sensor networks use verification and optimization methods. The processes and predictive analytics can be automated using big data approaches and increase many activities in the real time. This chapter covers the IoT technologies used for developing systems that support different agricultural processes, its applications for agriculture, challenges that IoT faces and future scope for upgradations of IoT in agriculture segment.
- 28 January 2021
- Published by Taylor & Francis
- p. 93-100
Open AccessIoT in agriculture
The internet of things (IoT) has plentiful applications in different fields. The initiative of IoT has shown a novel track of advanced research in agricultural dominion which is capable of offering many solutions toward the modernization of agriculture. Data are captured by mobile devices and sensors; for broadcasting data radio frequency (RF) technologies are used. To be persistent and functional in an effective way, sensor networks use verification and optimization methods. The processes and predictive analytics can be automated using big data approaches and increase many activities in the real time. This chapter covers the IoT technologies used for developing systems that support different agricultural processes, its applications for agriculture, challenges that IoT faces and future scope for upgradations of IoT in agriculture segment.
- Open Access
- 28 June 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0199665
Tissue and serum expression of TGM-3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemo-radiotherapy
Radioresistance is one of the main determinants of treatment outcome in oral squamous cell carcinoma (OSCC), but its prediction is difficult. Several authors aimed to establish radioresistant OSCC cell lines to identify genes with altered expression in response to radioresistance. The development of OSCC is a multistep carcinogenic process that includes activation of several oncogenes and inactivation of tumour suppressor genes. TGM-3 is a tumour suppressor gene and contributes to carcinogenesis process. The aim of this study was to estimate serum and tissue expression of TGM-3 and its correlation with clinico-pathological factors and overall survival in patients of OSCC undergoing chemo-radiotherapy. Tissue expression was observed in formalin fixed tissue biopsies of 96 cases of OSCC and 32 healthy controls were subjected to immunohistochemistry (IHC) by using antibody against TGM-3 and serum level was estimated by ELISA method. mRNA expression was determined by using Real-Time PCR. Patients were followed for 2 year for chemo radiotherapy response. In OSCC, 76.70% cases and in controls 90.62% were positive for TGM-3 IHC expression. TGM-3 expression was cytoplasmic and nuclear staining expressed in keratinized layer, stratum granulosum and stratum spinosum in controls and tumour cells. Mean serum TGM-3 in pre chemo-radiotherapy OSCC cases were 1304.83±573.55, post chemo-radiotherapy samples were 1530.64±669.33 and controls were 1869.16±1377.36, but difference was significant in pre chemo-radiotherapy samples as compared to controls (p<0.018). This finding was also confirmed by real- time PCR analysis in which down regulation (-7.92 fold change) of TGM-3 in OSCC as compared to controls. TGM-3 expression was significantly associated with response to chemo-radiotherapy treatment (p<0.007) and overall survival (p<0.015). Patents having higher level of TGM-3 expression have good response to chemo-radiotherapy and also have better overall survival. TGM-3 may serve as a candidate biomarker for responsiveness to chemo-radiotherapy treatment in OSCC patients.
- 28 June 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0199665
Open AccessTissue and serum expression of TGM-3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemo-radiotherapy
Radioresistance is one of the main determinants of treatment outcome in oral squamous cell carcinoma (OSCC), but its prediction is difficult. Several authors aimed to establish radioresistant OSCC cell lines to identify genes with altered expression in response to radioresistance. The development of OSCC is a multistep carcinogenic process that includes activation of several oncogenes and inactivation of tumour suppressor genes. TGM-3 is a tumour suppressor gene and contributes to carcinogenesis process. The aim of this study was to estimate serum and tissue expression of TGM-3 and its correlation with clinico-pathological factors and overall survival in patients of OSCC undergoing chemo-radiotherapy. Tissue expression was observed in formalin fixed tissue biopsies of 96 cases of OSCC and 32 healthy controls were subjected to immunohistochemistry (IHC) by using antibody against TGM-3 and serum level was estimated by ELISA method. mRNA expression was determined by using Real-Time PCR. Patients were followed for 2 year for chemo radiotherapy response. In OSCC, 76.70% cases and in controls 90.62% were positive for TGM-3 IHC expression. TGM-3 expression was cytoplasmic and nuclear staining expressed in keratinized layer, stratum granulosum and stratum spinosum in controls and tumour cells. Mean serum TGM-3 in pre chemo-radiotherapy OSCC cases were 1304.83±573.55, post chemo-radiotherapy samples were 1530.64±669.33 and controls were 1869.16±1377.36, but difference was significant in pre chemo-radiotherapy samples as compared to controls (p<0.018). This finding was also confirmed by real- time PCR analysis in which down regulation (-7.92 fold change) of TGM-3 in OSCC as compared to controls. TGM-3 expression was significantly associated with response to chemo-radiotherapy treatment (p<0.007) and overall survival (p<0.015). Patents having higher level of TGM-3 expression have good response to chemo-radiotherapy and also have better overall survival. TGM-3 may serve as a candidate biomarker for responsiveness to chemo-radiotherapy treatment in OSCC patients.
- 1 September 2012
- Published by Elsevier in Journal of Oral Biology and Craniofacial Research
- Vol. 2 (3) , 159-162
Effect of tobacco, alcohol, and smoking habits in oral precancer with histological proven epithelial dysplasia
- 1 September 2012
- Published by Elsevier in Journal of Oral Biology and Craniofacial Research
- Vol. 2 (3) , 159-162
Effect of tobacco, alcohol, and smoking habits in oral precancer with histological proven epithelial dysplasia